(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 November 2013 (14.11.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/167669 A1

(51) International Patent Classification:
C07K 16/36 (2006.01)

(21) International Application Number:
PCT/EP2013/059618

(22) International Filing Date:
8 May 2013 (08.05.2013)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

12167438.6	10 May 2012 (10.05.2012)	EP
12181697.9	24 August 2012 (24.08.2012)	EP
13150361.7	7 January 2013 (07.01.2013)	EP
61/817,675	30 April 2013 (30.04.2013)	US

(71) Applicant: **BAYER PHARMA AKTIENGESELLSCHAFT** [DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(72) Inventors: **WILMEN, Andreas**; Arndtstr. 5, 50676 Köln (DE). **STRAßBURGER, Julia**; Mozartstr. 7, 42115 Wuppertal (DE). **DITTMER, Frank**; Sandstr. 4, 40627 Düsseldorf (DE). **STRERATH, Michael**; Marc-Chagall-Str.86, 40477 Düsseldorf (DE). **BUCHMÜLLER, Anja**; Baderweg 72a, 45259 Essen (DE). **GRUDZINSKA-GOEBEL, Joanna**; Liselotte-Herrmannstr. 11, 10407 Berlin (DE). **FINNERN, Ricarda**; Dreiländerweg 107, 52074 Aachen (DE). **SCHÄFER, Martina**; Gurnemanzpfad 77, 13465 Berlin (DE). **GERDES, Christoph**; Düsseldorfer Str. 75, 51063 Köln (DE). **JÖRIßEN, Hannah**; Steinbeck 48, 45239 Essen (DE). **ITAKURA, Asako**; 235 SW Hooker St. Apt 7, Portland, OR 97201 (US). **Y. LEUNG, Philberta**; 3449 SE Yamhill Street, Portland, OR 97214 (US). **TUCKER, Erik**; 1511 SW Park Ave. Apt. 1307, Portland, OR 97201 (US).

(74) Agent: **BIP PATENTS**; c/o Bayer Intellectual Property GmbH, Creative Campus Monheim, Alfred-Nobel-Str. 10, 40789 Monheim (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: ANTIBODIES CAPABLE OF BINDING TO THE COAGULATION FACTOR XI AND/OR ITS ACTIVATED FORM FACTOR XIA AND USES THEREOF

(57) Abstract: The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation.

WO 2013/167669 A1